{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:19:52Z","timestamp":1784575192284,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":646,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1093\/annonc\/mdy030","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T12:09:32Z","timestamp":1517227772000},"page":"973-978","source":"Crossref","is-referenced-by-count":36,"title":["Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients"],"prefix":"10.1016","volume":"29","author":[{"given":"C.","family":"R\u00f6llig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gabrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kullmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fetscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mantovani-L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Kr\u00fcmpelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Heits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.S.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1093\/annonc\/mdy030_bb0010","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1093\/annonc\/mdy030_bb0015","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy030_bb0020","first-page":"1441","article-title":"Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study","volume":"69","author":"Preisler","year":"1987","journal-title":"Blood"},{"issue":"13","key":"10.1093\/annonc\/mdy030_bb0025","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy030_bb0030","series-title":"Treatment of acute myeloid leukemia (AML) in patients upper the age of 60 years report of the AML97-#38 Study of the East German Hematology and Oncology Study Group (OSHO) In Proceedings of the ASH Annual Meeting Abstracts","author":"Niederwieser","year":"2002"},{"issue":"2","key":"10.1093\/annonc\/mdy030_bb0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10428190290006035","article-title":"Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I\u2013II study","volume":"43","author":"Mantovani","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1093\/annonc\/mdy030_bb0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy030_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7000","article-title":"Final results of a phase III randomized trial of VYXEOS (CPX-351) versus 7+3 in older patients with newly diagnosed high-risk (secondary) AML","volume":"34","author":"Lancet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy030_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-015-2045-8","article-title":"Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)","volume":"142","author":"Kahl","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdy030_bb0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood.V128.22.901.901","article-title":"SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML)","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1093\/annonc\/mdy030_bb0060","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2007-06-095844","article-title":"Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy030_bb0065","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1093\/annonc\/mdy030_bb0070","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2015.61.5187","article-title":"Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer","volume":"33","author":"Feijen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy030_bb0075","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/leu.2016.25","article-title":"Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia","volume":"30","author":"Krug","year":"2016","journal-title":"Leukemia"},{"issue":"17","key":"10.1093\/annonc\/mdy030_bb0080","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419454756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419454756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/4\/973\/24702655\/mdy030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:40:59Z","timestamp":1624700459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419454756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0923753419454756"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy030","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}